8-K: NewAmsterdam Pharma Announces Positive Phase 3 Trial Results for Obicetrapib, Showing Significant LDL-C Reduction and Potential Cardiovascular Benefits

NewAmsterdam Pharma's Phase 3 BROADWAY trial demonstrated a statistically significant 33% reduction in LDL-C with obicetrapib, along with a 21% observed reduction in major adverse cardiovascular events.

Summary

• NewAmsterdam Pharma announced positive topline results from its Phase 3 BROADWAY clinical trial for obicetrapib.
• The trial evaluated obicetrapib in adult patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia whose LDL-C was not adequately controlled despite being on maximally tolerated lipid-lowering therapy.
• The primary endpoint was achieved with a statistically significant 33% reduction in LDL-C at day 84 compared to placebo (p<0.0001).
• A 21% reduction in major adverse cardiovascular events (MACE) favoring obicetrapib was observed at one year.
• Obicetrapib was well-tolerated, with safety results comparable to placebo.
• The trial included 2,530 patients randomized 2:1 to receive 10 mg obicetrapib or placebo.
• The mean baseline LDL-C for enrolled patients in the obicetrapib arm was approximately 100 mg/dL.
• Secondary endpoints also showed significant reductions in ApoB, Lp(a), non-HDL-C, and total cholesterol at day 84.
• LDL-C levels at days 180 and 365 showed a mean reduction of -34% and an imputed LS mean of -24%, respectively (p<0.0001).

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with significant LDL-C reduction and a promising signal for cardiovascular benefit. The safety profile is also favorable, making this a very positive announcement for the company.

Positives

• Obicetrapib demonstrated a significant 33% reduction in LDL-C, meeting the primary endpoint of the BROADWAY trial.
• The observed 21% reduction in major adverse cardiovascular events suggests a potential benefit beyond LDL-C lowering.
• The safety profile of obicetrapib was comparable to placebo, indicating good tolerability.
• The drug showed consistent LDL-C reduction over one year of treatment.
• Obicetrapib has shown consistent benefit in clinical trials across a variety of drivers of cardiovascular risk.
• The treatment discontinuation rate for the obicetrapib arm was 11.1% versus 12.4% for placebo, indicating good tolerability.
• The observed changes in other biomarkers, including HDL-C, non-HDL-C, Lp(a), ApoB, and ApoA1, were consistent with prior trials.

Negatives

• MACE was not a primary or secondary endpoint of the BROADWAY trial, so the 21% reduction is an exploratory finding.
• There were slightly more deaths in the obicetrapib arm (19) compared to the placebo arm (12), although this was not statistically significant.
• The treatment discontinuation rate for the obicetrapib arm was 11.1% versus 12.4% for placebo, indicating some patients did not tolerate the drug.
• There were slightly more treatment-emergent serious adverse events in the obicetrapib arm (211) compared to the placebo arm (117).

Risks

• The MACE data is from an exploratory endpoint and may not be predictive of the results of the PREVAIL cardiovascular outcomes trial.
• The company is subject to risks related to the approval of its product candidate and the timing of expected regulatory and business milestones.
• There are risks associated with the company's efforts to commercialize a product candidate.
• The company faces competition from other product candidates.
• There are risks related to the company's ability to attract and retain qualified personnel.
• The company's ability to continue to source the raw materials for its product candidate is a risk.

Future Outlook

NewAmsterdam plans to present additional BROADWAY and TANDEM data at upcoming scientific sessions and meet with regulatory authorities to discuss filings for obicetrapib. The company is also awaiting results from the PREVAIL cardiovascular outcomes trial.

Management Comments

• Michael Davidson, M.D., CEO of NewAmsterdam, stated that the company's aspiration was that the Phase 3 trials would confirm the efficacy and tolerability observed in Phase 2 and differentiate obicetrapib from other LDL-C lowering therapies.
• John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam, expressed excitement about the safety profile of obicetrapib and the potential benefit beyond LDL-C lowering.
• Stephen Nicholls, M.B.B.S., Ph.D., Director, Monash Victorian Heart Institute, highlighted the transformative potential of obicetrapib as a treatment option for dyslipidemia.

Industry Context

The announcement comes amid a growing need for effective LDL-C lowering therapies, as many patients are not achieving target levels despite existing treatments. Cardiovascular disease remains the leading cause of death globally, and the results of the BROADWAY trial suggest obicetrapib could be a significant advancement in this area.

Comparison to Industry Standards

• The 33% LDL-C reduction observed in the BROADWAY trial is comparable to or better than some other non-statin therapies currently available.
• The observed 21% reduction in MACE is a promising signal, as many existing therapies primarily focus on LDL-C reduction without demonstrating such a significant impact on cardiovascular events.
• The safety profile of obicetrapib, being comparable to placebo, is a key differentiator from some other lipid-lowering therapies that may have more significant side effects.
• The results are particularly relevant given that less than 25% of patients with ASCVD achieve an LDL-C goal of less than 70mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL, highlighting the unmet need that obicetrapib could address.
• The company's previous trials, such as ROSE2, TULIP, ROSE, and OCEAN, also showed statistically significant LDL-lowering with a similar side effect profile to placebo, indicating a consistent trend in the drug's performance.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with cardiovascular disease and/or heterozygous familial hypercholesterolemia may benefit from a new treatment option.
• Employees of NewAmsterdam Pharma may be motivated by the positive results and the potential for commercial success.
• The medical community may view obicetrapib as a significant advancement in lipid-lowering therapy.

Next Steps

• NewAmsterdam plans to present additional results from BROADWAY at an upcoming medical conference.
• The company intends to publish the data in a major medical journal.
• NewAmsterdam will meet with regulatory authorities to discuss filings for obicetrapib.
• The company will continue to monitor the PREVAIL cardiovascular outcomes trial.

Key Dates

Keywords

Obicetrapib, LDL-C, Cardiovascular Disease, Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Lipid-Lowering Therapy, MACE, Clinical Trial, Phase 3, Cholesterol